GlassScriptPhysician profile
Mary Champion
NPI 1760779722
$2,904.66
in general payments reported to CMS, 2019-2025
21 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $53.31 · 2021: $388 · 2022: $325 · 2023: $515 · 2024: $699 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $536.87 | 2022-2025 | Vabysmo, Susvimo |
| Alimera Sciences, INC. | $490.23 | 2019-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $323.40 | 2019-2025 | Clareon |
| Carl Zeiss Meditec USA, INC. | $222.29 | 2022-2024 | |
| Allergan, INC. | $206.20 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $179.11 | 2021 | |
| Ani Pharmaceuticals, INC. | $156.61 | 2025 | Purified Cortrophin Gel |
| Sun Pharmaceutical Industries INC. | $139.14 | 2023-2024 | Cequa |
| Regeneron Healthcare Solutions, INC. | $137.71 | 2019-2024 | Eylea |
| Abbvie INC. | $119.57 | 2025 | |
| Novartis Pharmaceuticals Corporation | $113.42 | 2019 | |
| Dompe US, INC. | $58.32 | 2024 | Oxervate |
| Astellas Pharma US INC | $43.69 | 2023 | |
| Apellis Pharmaceuticals, INC. | $36.70 | 2023-2024 | Syfovre |
| Bausch & Lomb Americas INC. | $22.78 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $21.14 | 2023 | |
| Genmab U.S., INC. | $20.78 | 2023 | Tivdak |
| Harrow Eye, LLC | $20.66 | 2025 | Iheezo |
| Sight Sciences, INC. | $20.22 | 2024 | Omni Surgical System |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $16.42 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Champion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.